Marker Therapeutics
MRKR
73 hedge funds and large institutions have $87.6M invested in Marker Therapeutics in 2019 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 15 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
44% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $840K
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
4% more funds holding
Funds holding: 70 → 73 (+3)
0.04% more ownership
Funds ownership: 3.71% → 3.75% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
34% less capital invested
Capital invested by funds: $134M → $87.6M (-$46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.21M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$954K |
| 3 |
Morgan Stanley
New York
|
+$857K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$761K |
| 5 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$591K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$4.43M |
| 2 |
OCM
Osterweis Capital Management
San Francisco,
California
|
-$945K |
| 3 |
ACA
Apis Capital Advisors
New York
|
-$713K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$580K |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
-$539K |
MRKR Hedge Fund Activity: Q3 2019 in Review
73 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q3 2019, worth a combined $87.6M — down 34% from $134M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new MRKR positions and 15 closed out — a net gain of 3 holders — while 23 added to existing stakes and 11 trimmed.
The largest buyer was Northern Trust, adding an estimated $1.21M. The largest seller was 683 Capital Management, exiting entirely with an estimated $4.43M sold.
- 73 institutional investors held Marker Therapeutics (MRKR) as of Q3 2019, up from 70 in Q2 2019.
- Funds reported $87.6M of Marker Therapeutics stock for Q3 2019, down 34% quarter-over-quarter.
- 18 funds opened new Marker Therapeutics positions in Q3 2019 and 15 closed out, a net change of +3 holders.
- The largest Marker Therapeutics buyer in Q3 2019 was Northern Trust, an estimated $1.21M added.
- The largest Marker Therapeutics seller in Q3 2019 was 683 Capital Management, an estimated $4.43M sold.
Based on aggregated 13F filings for Q3 2019.